Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Amgen's Prolia Complete Response submission: FDA classifies and sets PDUFA date

Amgen Inc. today announced that the U.S. Food and Drug Administration (FDA) has evaluated the content of the Company's Complete Response submission for Prolia™ (denosumab) in the treatment of postmenopausal osteoporosis and classified it as a Class 2 resubmission. With the Class 2 designation, the FDA set a corresponding Prescription Drug User Fee Act (PDUFA) action date of July 25, 2010.

20 Feb 2010

BioCrossroads' Indiana Seed Fund invests $400,000 in Bioscience Vaccines

BioCrossroads' Indiana Seed Fund has invested in Bioscience Vaccines, Inc. to accelerate the development of biologic materials, which may boost the effectiveness of a wide range of life-saving vaccines.

19 Feb 2010

11 cities to join DASH FOR DAD national race series to end prostate cancer

DASH FOR DAD, the premier prostate cancer race series in the U.S., is a heartfelt tight-knit community event that brings together athletes, cancer survivors, physicians, caregivers, family members and friends. Proceeds from each 10K race are used to provide free prostate cancer testing for men in the local community of the event.

19 Feb 2010

Roseville ROC commences cancer treatment with Elekta VMAT

The first treatments with Elekta Volumetric Modulated Arc Therapy (VMAT) began November 17, 2009 at Roseville Radiation Oncology Center (ROC) at Radiological Associates of Sacramento (RAS). RAS, a large private medical group, includes diagnostics as well as therapy in its centers. ROC treats 30-35 patients per day, mainly with prostate and breast lesions.

From Elekta 19 Feb 2010

Researcher develops acoustic resonant sensor that can test bodily fluids for variety of diseases

What if it were possible to go to the store and buy a kit to quickly and accurately diagnose cancer, similar to a pregnancy test? A University of Missouri researcher is developing a tiny sensor, known as an acoustic resonant sensor, that is smaller than a human hair and could test bodily fluids for a variety of diseases, including breast and prostate cancers.

18 Feb 2010

Researchers discover new prognosis marker for prostate cancer

Measuring levels of the active form of the protein EGFR in the tumor and its vicinity can provide a more reliable prognosis for individuals with prostate cancer.

18 Feb 2010

Soligenix' LPM oral drug delivery technology receives Hong Kong patent

Soligenix, Inc., a late-stage biotechnology company, announced today that it has received a Hong Kong patent which addresses its Lipid Polymer Micelle (LPM™) technology for the improved oral delivery of drugs. The issued Hong Kong patent, HK 1071054, entitled "Stabilized Reverse Micelle Compositions and Uses Thereof" covers lipid structures (reverse micelles) that promote the intestinal absorption of peptides and other sensitive drugs that cannot otherwise be given orally.

17 Feb 2010

Phase II clinical trial result of abiraterone drug shows promise for advanced prostate cancer

New results from a phase II clinical trial of the prostate cancer drug abiraterone suggest that it may help men with advanced disease who have tried standard treatments.

17 Feb 2010

Study: Earlier detection of lung cancer can reduce number of late stage lung cancer deaths

The first ever actuarial analysis of lung cancer mortality, published today in Population Health Management Journal, provides strong evidence that earlier detection could reduce the number of late stage lung cancer deaths by over 70,000 people each year in the US.

17 Feb 2010

Calypso real-time tumor tracking system usage during IMRT for prostate cancer reduces rectal/urinary side effects

Calypso Medical Technologies, Inc., a developer of targeting technology used for accurate, precise real-time tracking of tumor targets, today announced the online publication of a clinical study in Urology (The GOLD JOURNAL). The prospective, multi-site study, entitled, “Assessing the Impact of Margin Reduction (AIM),” is the first outcomes-based study to evaluate the quality of life of high-dose intensity-modulated radiotherapy (IMRT) to the prostate with tightly contoured treatment technically described as “reduced treatment margins.”

17 Feb 2010

New fluorescent probes improve tumor detection in mice

Building on his Nobel Prize-winning work creating fluorescent proteins that light up the inner workings of cells, a team of researchers led by Howard Hughes Medical Institute investigator Roger Tsien, PhD, professor of pharmacology, chemistry and biochemistry at the University of California, San Diego and the Moores UCSD Cancer Center has developed biological probes that can stick to and light up tumors in mice.

17 Feb 2010

CNRS-Institut researchers identify 'virulence factor' that inhibits host immune response

Oncogenic retroviruses are a particular family of viruses that can cause some types of cancer. Thierry Heidmann and his colleagues in the CNRS-Institut Gustave Roussy-Université Paris Sud 11 "Rétrovirus endogènes et éléments rétroïdes des eucaryotes supérieurs" Laboratory have studied these viruses. They have identified a "virulence factor" that inhibits the host immune response and allows the virus to spread throughout the body.

16 Feb 2010

New conference to discuss issues surrounding breast cancer to take place at UWE

An opportunity to join a forum to discuss issues surrounding breast cancer is taking place at the University of the West of England on Saturday 3 July 2010.

15 Feb 2010

CROF, sanofi-aventis announce the creation of CASARIA for cancer research

The Canadian Radiation Oncology Foundation and sanofi-aventis are pleased to announce the creation of the Canadian Radiation Oncology Foundation/Sanofi-Aventis Research Innovation Award (CASARIA).

15 Feb 2010

Research roundup: Bundled payments, PTSD incidence, cost of treating immigrants

This paper examines the spending for health care of adult naturalized citizens and immigrant noncitizens (including some undocumented immigrants) compared to U.S. natives, as documented in data from the 1999-2006 Medical Expenditure Panel Surveys (MEPS): "inflation and age-adjusted health care expenditures among noncitizen immigrants were consistently … lower than those of naturalized citizens and U.S. natives during 1999-2006."

15 Feb 2010

Histone modifications associated with pancreatic cancer development and progression

Specific chemical modifications to proteins called histones, which are found in the nucleus of cells and act as spools around which DNA is wound, can be used to predict prognosis and response to treatment in subsets patients with pancreatic cancer, a study by researchers at UCLA's Jonsson Comprehensive Cancer Center has found.

12 Feb 2010

PAN to provide co-payment assistance for medications to underinsured patients through five new funds

Patient Access Network Foundation will expand its services to provide co-payment assistance for medications to underinsured patients through five new funds -- including grants of up to $10,000 per year for prostate cancer patients.

12 Feb 2010

Theragenics announces record $18.7M consolidated revenue for fourth-quarter 2009

Theragenics Corporation, a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the fourth quarter and year ended December 31, 2009. Consolidated results include the results of NeedleTech Products, Inc. (“NeedleTech”) subsequent to its acquisition by Theragenics on July 28, 2008.

11 Feb 2010

HDC signs agreement to receive clinical specimens for colon cancer molecular diagnostic test

Health Discovery Corporation announced today that the Company has entered into an exclusive agreement with the Pancreas, Biliary and Liver Surgery Center of New York at Saint Vincent Catholic Medical Centers in New York City to provide clinical specimens to be utilized to complete the final validation of HDC's molecular diagnostic test for colon cancer. This test demonstrated a 93% Sensitivity and a 93% Specificity in a previous validation study.

11 Feb 2010

Principio, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center sign technology licensing agreement

Principio Inc., a privately held emerging company developing novel molecular imaging agents and therapeutic radiopharmaceuticals for the treatment of cancer, today announced that the Company has obtained an exclusive license to several technologies developed at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.

11 Feb 2010

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Amgen's Prolia Complete Response submission: FDA classifies and sets PDUFA date

BioCrossroads' Indiana Seed Fund invests $400,000 in Bioscience Vaccines

11 cities to join DASH FOR DAD national race series to end prostate cancer

Roseville ROC commences cancer treatment with Elekta VMAT

Researcher develops acoustic resonant sensor that can test bodily fluids for variety of diseases

Researchers discover new prognosis marker for prostate cancer

Soligenix' LPM oral drug delivery technology receives Hong Kong patent

Phase II clinical trial result of abiraterone drug shows promise for advanced prostate cancer

Study: Earlier detection of lung cancer can reduce number of late stage lung cancer deaths

Calypso real-time tumor tracking system usage during IMRT for prostate cancer reduces rectal/urinary side effects

New fluorescent probes improve tumor detection in mice

CNRS-Institut researchers identify 'virulence factor' that inhibits host immune response

New conference to discuss issues surrounding breast cancer to take place at UWE

CROF, sanofi-aventis announce the creation of CASARIA for cancer research

Research roundup: Bundled payments, PTSD incidence, cost of treating immigrants

Histone modifications associated with pancreatic cancer development and progression

PAN to provide co-payment assistance for medications to underinsured patients through five new funds

Theragenics announces record $18.7M consolidated revenue for fourth-quarter 2009

HDC signs agreement to receive clinical specimens for colon cancer molecular diagnostic test

Principio, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center sign technology licensing agreement

What to know about prostate cancer eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in